PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation

Journal of Experimental Medicine

Volumn 211, Issue 5, 2014, Pages 781-790

  Noman, Muhammad Zaeem ^a   Desantis, Giacomo ^b   Janji, Bassam ^c   Hasmim, Meriem ^a   Karray, Saoussen ^a   Dessen, Philippe ^d   Bronte, Vincenzo ^e   Chouaib, Salem ^a  

^a INSERM   (France)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 10; INTERLEUKIN 6; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CHROMATIN IMMUNOPRECIPITATION; COMPARATIVE STUDY; CONSENSUS SEQUENCE; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HYPOXIA; LUCIFERASE ASSAY; LYMPHOID ORGAN; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SPLEEN CELL; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR MICROENVIRONMENT; UPREGULATION;

ANIMALS; ANTIGENS, CD274; CELL HYPOXIA; CHROMATIN IMMUNOPRECIPITATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUCIFERASES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MYELOID CELLS; ORGANIC CHEMICALS; REAL-TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84899753178     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20131916     Document Type: Article

References (23)

1. Apolloni, E., V. Bronte, A. Mazzoni, P. Serafini, A. Cabrelle, D.M. Segal, H.A. Young, and P. Zanovello. 2000. Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J. Immunol. 165:6723-6730.
2. Brahmer, J.R., S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, P. Hwu, C.G. Drake, L.H. Camacho, J. Kauh, K. Odunsi, et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366:2455-2465. http://dx.doi.org/10.1056/NEJMoa1200694
3. Clambey, E.T., E.N. McNamee, J.A. Westrich, L.E. Glover, E.L. Campbell, P. Jedlicka, E.F. de Zoeten, J.C. Cambier, K.R. Stenmark, S.P. Colgan, and H.K. Eltzschig. 2012. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc. Natl. Acad. Sci. USA. 109:E2784-E2793. http://dx.doi.org/10.1073/pnas.1202366109
4. Corzo, C.A., T. Condamine, L. Lu, M.J. Cotter, J.I. Youn, P. Cheng, H.I. Cho, E. Celis, D.G. Quiceno, T. Padhya, et al. 2010. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207:2439-2453. http://dx.doi.org/10.1084/jem.20100587
5. Curiel, T.J., S. Wei, H. Dong, X. Alvarez, P. Cheng, P. Mottram, R. Krzysiek, K.L. Knutson, B. Daniel, M.C. Zimmermann, et al. 2003. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9:562-567. http://dx.doi.org/10.1038/nm863
6. Doedens, A.L., C. Stockmann, M.P. Rubinstein, D. Liao, N. Zhang, D.G. DeNardo, L.M. Coussens, M. Karin, A.W. Goldrath, and R.S. Johnson. 2010. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 70:7465-7475. http://dx.doi.org/10.1158/0008-5472.CAN-10-1439
7. duPre', S.A., D. Redelman, and K.W. Hunter Jr. 2008. Microenvironment of the murine mammary carcinoma 4T1: endogenous IFN-gamma affects tumor phenotype, growth, and metastasis. Exp. Mol. Pathol. 85:174-188. http://dx.doi.org/10.1016/j.yexmp.2008.05.002
8. Fujimura, T., S. Ring, V. Umansky, K. Mahnke, and A.H. Enk. 2012. Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas. J. Invest. Dermatol. 132:1239-1246. http://dx.doi.org/10.1038/jid.2011.416
9. Gabrilovich, D.I., S. Ostrand-Rosenberg, and V. Bronte. 2012. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12:253-268. http://dx.doi.org/10.1038/nri3175
10. Greenwald, R.J., G.J. Freeman, and A.H. Sharpe. 2005. The B7 family revisited. Annu. Rev. Immunol. 23:515-548. http://dx.doi.org/10.1146/annurev.immunol.23.021704.115611
11. Haile, S.T., J.J. Bosch, N.I. Agu, A.M. Zeender, P. Somasundaram, M.K. Srivastava, S. Britting, J.B. Wolf, B.R. Ksander, and S. Ostrand-Rosenberg. 2011. Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80. J. Immunol. 186:6822-6829. http://dx.doi.org/10.4049/jimmunol.1003682
12. Hart, K.M., K.T. Byrne, M.J. Molloy, E.M. Usherwood, and B. Berwin. 2011. IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer. Front Immunol. 2:29. http://dx.doi.org/10.3389/fimmu.2011.00029
13. Imtiyaz, H.Z., E.P. Williams, M.M. Hickey, S.A. Patel, A.C. Durham, L.J. Yuan, R. Hammond, P.A. Gimotty, B. Keith, and M.C. Simon. 2010. Hypoxiainducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J. Clin. Invest. 120:2699-2714. http://dx.doi.org/10.1172/JCI39506
14. Kapitsinou, P.P., Q. Liu, T.L. Unger, J. Rha, O. Davidoff, B. Keith, J.A. Epstein, S.L. Moores, C.L. Erickson-Miller, and V.H. Haase. 2010. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood. 116:3039-3048. http://dx.doi.org/10.1182/blood-2010-02-270322
15. Lee, S.J., B.C. Jang, S.W. Lee, Y.I. Yang, S.I. Suh, Y.M. Park, S. Oh, J.G. Shin, S. Yao, L. Chen, and I.H. Choi. 2006. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett. 580:755-762. http://dx.doi.org/10.1016/j.febslet.2005.12.093
16. Noman, M.Z., S. Buart, J. Van Pelt, C. Richon, M. Hasmim, N. Leleu, W.M. Suchorska, A. Jalil, Y. Lecluse, F. El Hage, et al. 2009. The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J. Immunol. 182:3510-3521. http://dx.doi.org/10.4049/jimmunol.0800854
17. Noman, M.Z., S. Buart, P. Romero, S. Ketari, B. Janji, B. Mari, F. Mami-Chouaib, and S. Chouaib. 2012. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res. 72:4629-4641. http://dx.doi.org/10.1158/0008-5472.CAN-12-1383
18. Okazaki, T., and T. Honjo. 2007. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19:813-824. http://dx.doi.org/10.1093/intimm/dxm057
19. Pardoll, D.M. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 12:252-264. http://dx.doi.org/10.1038/nrc3239
20. Semenza, G.L. 2011. Oxygen sensing, homeostasis, and disease. N. Engl. J. Med. 365:537-547. http://dx.doi.org/10.1056/NEJMra1011165
21. Topalian, S.L., F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, J.D. Powderly, R.D. Carvajal, J.A. Sosman, M.B. Atkins, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366:2443-2454. http://dx.doi.org/10.1056/NEJMoa1200690
22. West, E.E., H.T. Jin, A.U. Rasheed, P. Penaloza-Macmaster, S.J. Ha, W.G. Tan, B. Youngblood, G.J. Freeman, K.A. Smith, and R. Ahmed. 2013. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J. Clin. Invest. 123:2604-2615. http://dx.doi.org/10.1172/JCI67008
23. Youn, J.I., S. Nagaraj, M. Collazo, and D.I. Gabrilovich. 2008. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181: 5791-5802.